October 19, 2022 | Published by bit.bio
Mark Kotter with other panelist after the codex talks.
CAMBRIDGE, Wednesday 19 October 2022 - bit.bio founder and CEO Dr Mark Kotter was invited to the Codex Talk World's Top 50 Innovators 2022 event in London. He had just 15 minutes to answer the question "How can we program biology as software to develop affordable next generation cell therapies?"
Dr Kotter said that a reliable source of human cells can change the way we discover drugs. If we take an Alzheimer for example - currently drugs are developed in mice that don’t get Alhzeimer’s.
Imagine, we can actually use cells that are affected by the conditions we want to treat? The chances of success will be much higher. This is extremely important, because our biomedical knowledge is growing exponentially, and we need to get better at developing new medicines.
Our approach is unique in the cell therapy industry because we are starting with the fundamental building block of these medicines - the cell. Not the disease or drug target. This approach will democratise access to human cells for the cell therapy industry so we can finally bring this third generation of medicines to every patient everywhere.
Learn more in the video below.